- Company
- Supect by Il-Yang Pharm reduces COVID-19 by 70%
- by Jung, Hye-Jin Mar 17, 2020 06:27am
- Research has shown that Il-Yang Pharm's 'Supect' has the effect of reducing the COVID-19. Il-Yang Pharm announced on the 13th that as a result of experimenting with COVID-19 received from the KCDC, the virus in the group using Supect decreased by 70% within 48 hours. Supect (Radotinib) by Il-Yang Pharm is a leukemia treatment agent. This
- Company
- Herceptin market recovers ￦100 billion in three years
- by An, Kyung-Jin Mar 16, 2020 06:31am
- Domestically developed biosimilars enter the blockbuster anti-cancer drug 'Herceptin' market. The market share of the two products 'Herzuma' and 'Sampenet' exceeded 28%. The market size of Trastuzumab that Celltrion developed as 'Herjuma' shrank with the expansion of the biosimilar market has recovered to the level before drug price cuts.
- Company
- Why Ezetimibe combination drug for dyslipidemia?
- by Eo, Yun-Ho Mar 16, 2020 06:30am
- For some diseases, combination drugs are vastly preferred than the other. Dipeptidyl peptidase-4 inhibitor plus metformin combination for patients with diabetes, and angiotensin II receptor blocker (ARB) plus calcium channel blocker (CCB) plus alpha combination for patients with hypertension haven taken over significant part of respectiv
- Company
- Handok tops KRW 30 bln PAH treatment market
- by Nho, Byung Chul Mar 16, 2020 06:27am
- Korean pharmaceutical industry is closely paying attention to Handok’s market share constantly growing in pulmonary arterial hypertension (PAH) treatment sector. In 2019, Korean PAH treatment market volume was recorded at 30.7 billion won with 20 percent bump from the previous year. In the market, Handok’s PAH line up&8212;Traclear (6
- Company
- “Lynparza now available for unmet medical needs in TNBC"
- by Eo, Yun-Ho Mar 13, 2020 06:32am
- “Breast cancer has various treatment options.” True, but not always for all types of breast cancer. Since the release of Herceptin (trastuzumab), human epidermal growth factor receptor 2-positive (HER2+) breast cancer treatment paradigm has been shifted and follow-on targeted therapies are continuing to enter the market. The launch of I
- Company
- Vibramycin & Cefdana are out of stock
- by Jung, Hye-Jin Mar 13, 2020 06:30am
- Some of rescription medicines are sold out. In particular, since Vibramycin-N sold out 500 tablets units in 2018, it is expected that units of 100 tablets will be out of stock, which will cause inconvenience to the prescription site. According to the distribution industry on the 11th, the re-supply of both 100 tablets unit and 500 tablets
- Company
- The Thai government has eased regulations on fillers
- by Kim, Jin-Gu Mar 13, 2020 06:30am
- Export of Hyaluronic acid filler to Thailand becomes easy. This is due to the Thai government's classification of hyaluronic acid fillers as medical devices, not pharmaceuticals, in Thailand starting tomorrow (11th). It is expected that domestic companies' entry into Thailand will accelerate as related certification requirements ease.
- Company
- Bukwang “Levovir as effective as Kaletra on COVID-19”
- by Lee, Seok-Jun Mar 13, 2020 06:30am
- On Mar. 10, Bukwang Pharmaceutical announced its new treatment for hepatitis B Levovir (clevudine) has demonstrated treament effect on par with HIV drug Kaletra, also used to treat COVID-19. According to the Korean company, Levovir has been tested in vitro on virus extracted from Korean COVID-19 patient’s samples. Kaletra’s active
- Company
- Venclexta will be prescribed in major hospitals soon
- by Eo, Yun-Ho Mar 12, 2020 06:07am
- Venclaxta, which is ready for insurance benefits, will be prescribed at a general hospital soon. According to the related industry, Abbvie's Chronic Lymphocytic Leukemia (CLL) treatment, Venclexta (Venetoclax), passed DC (drug committee) of 5 big major Hospitals such as Seoul National University Hospital, Seoul St. Mary's Hospital, Severan
- Company
- “No changes in safety and efficacy of montelukast”
- by Kim, Jin-Gu Mar 12, 2020 06:07am
- Medical academics argue there is “no change in safety and efficacy of montelukast,” currently controversial with safety risk. Director Kim Chang Geun of Inje Uniersity Sanggye Paik Hospital the Asthma and Allergies Center spoke on Mar. 9 at a roundtable with press. The President of Pneumonia and Respiratory Diseases Study Group at
